Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Clinical trial NCT04632758 · UNKNOWN
Trial details
- NCT number
- NCT04632758
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-01
- Primary completion
- 2024-12-01
- Enrollment
- 292
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.